Rankings
▼
Calendar
BIIB Q2 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q2 2023 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$2.5B
-5.1% YoY
Gross Profit
$1.9B
75.9% margin
Operating Income
$690M
28.1% margin
Net Income
$592M
24.1% margin
EPS (Diluted)
$4.07
QoQ Revenue Growth
-0.3%
Cash Flow
Operating Cash Flow
$487M
Free Cash Flow
$400M
Stock-Based Comp.
$74M
Balance Sheet
Total Assets
$25.2B
Total Liabilities
$10.7B
Stockholders' Equity
$14.5B
Cash & Equivalents
$2.6B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.5B
$2.6B
-5.1%
Gross Profit
$1.9B
$2.1B
-11.5%
Operating Income
$690M
$936M
-26.3%
Net Income
$592M
$1.1B
-44.1%
Revenue Segments
MS Product Revenues
$1.2B
43%
TYSABRI product
$483M
17%
SPINRAZA
$437M
15%
Fumarate
$400M
14%
Interferon
$302M
11%
Geographic Segments
Non-US
$1.0B
57%
UNITED STATES
$801M
43%
← FY 2023
All Quarters
Q3 2023 →